Pediatric Heart FailureEarly Phase 1PumpKINNCT02954497
Pumps for Kids, Infants, and Neonates
A Early Phase 1 study testing Surgical placement of the Jarvik 2015 VAD and Surgical Placement of Jarvik 2015 VAD in people with Pediatric Heart Failure, run by Carelon Research at 7 sites in United States.
Trial summary
PumpKIN is a multicenter, prospective, single-arm feasibility study; Evaluating the investigational Jarvik 2015 VAD in pediatric patients with heart failure. This feasibility trial will enroll 10 subjects at up to 7 sites in the US. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Pediatric Heart Failure
- What is being tested?
- Surgical placement of the Jarvik 2015 VAD and Surgical Placement of Jarvik 2015 VAD
- Type of treatment
- Medical device, Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 7 participants
- Where
- 7 sitesUnited States
- Study dates
- 22 Oct 2018to 15 Sep 2023
- Phase
- Early Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Children must meet all of the following criteria:
- Males and females within weight range 8 to 30 kg
- Body surface area (BSA) 0.4 m2 to 1.0 m2
- Cardiac Diagnosis:
- Standard Cardiac Anatomy : Two-ventricle circulation, including cardiomyopathy, repaired structural heart disease (e.g. anomalous left coronary artery from the pulmonary artery [ALCAPA], aortic stenosis) or acquired heart disease (e.g., myocarditis, Kawasaki disease)
- INTERMACS Profile 1 or 2 as evidenced by one or more of the following:
- Inability to wean from extra-corporeal membrane oxygenation (ECMO) or other temporary circulatory support (TCS), OR
- Inability to wean from mechanical ventilator support, OR
- Inotrope-dependent, decompensated heart failure AND meet one or more of the following criteria within 48 hours prior to implant (unless otherwise noted) which is attributed to decompensated heart failure despite optimal medical therapy:
- Urine output <0.5 cc/kg/hour for 12hr within 48 hours ii. Creatinine level >2 times the ULN for age iii. Alanine aminotransferase (ALT) or total bilirubin result >3 times the ULN for age (either qualifies the patient) iv. Mixed venous oxygen saturation (SvO2) <55% (or arteriovenous oxygen difference of >45%) in two repeated measurements v. Acidosis: Base excess >-5 in 2 or more measurements vi. Inability to tolerate appropriate enteral calories as prescribed by a registered dietician d. Inability to ambulate freely to participate fully in age-appropriate activities of daily living (ADLs) and/or cardiac rehabilitation/physical therapy
- LVAD support is intended for bridge-to transplant. Subject is listed for transplant or eligible (i.e., no medical or surgical contraindications) to be listed for cardiac transplant, United Network for Organ Sharing (UNOS) status 1A, or equivalent
- Written consent of parent(s) or legally authorized representative (LAR) where appropriate.
Children must not meet any of the following exclusion criteria within 48 hours prior to device implant:
- Known contraindication for systemic anticoagulation
- Currently participating in an interventional trial whose protocol prevents effective application of Jarvik 2015, potentially has an independent effect on trial endpoints, or otherwise interferes with execution of the PumpKIN protocol
- Stable inotrope dependence (INTERMACS profile 3)
- Single ventricle anatomy
- Presence of a mechanical heart valve
- Unresolved malignancy
- CPR with duration >30 consecutive minutes within 48 hours prior to device implant or CPR with uncertain neurological status prior to device implant
- Renal dysfunction that is severe or, in the opinion of the investigator, irreversible
- Hepatic dysfunction that is severe or, in the opinion of the investigator, irreversible
- Severe or irreversible pulmonary dysfunction
- ECMO use for >10 consecutive days
- Unrepairable severe aortic insufficiency
- Active, systemic infection unresponsive to antimicrobial therapy
- Known cerebrovascular event within the past 30 days or uncertain neurological status
- Severe right ventricular (RV) dysfunction or significant arrhythmia requiring treatment with an RV assist device (RVAD) (i.e., biventricular assist device)
- Unmanageable bleeding per judgment of the investigator
- Ventricular dysfunction that is likely to recover (e.g. myocarditis, metabolic myopathy where LV dysfunction is present solely with intermittent acidosis/crises).
- Left ventricular end-diastolic dimension or left ventricular end-diastolic volume z score of < +2.5 end-diastolic dimension or ventricular end-diastolic volume z score of < +3.0
- Left ventricular ejection fraction of >35%
Trial locations and contacts
7 sites in 1 country.
7 sites in 1 country
United States7 sites
Children's Healthcare of Atlanta
Atlanta, Georgia, 30322
Boston Children's Hospital
Boston, Massachusetts, 02115
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, 45229
Children's Medical Center - Dallas
Dallas, Texas, 75235
Texas Children's Hospital
Houston, Texas, 77030
Columbia University Medical Center
New York, New York, 10032
Lucile Packard Children's Hospital Stanford
Palo Alto, California, 94304
About this study
PumpKIN is a multicenter, prospective, single-arm feasibility study; Evaluating the investigational Jarvik 2015 VAD in pediatric patients with heart failure. This feasibility trial will enroll 10 subjects at up to 7 sites in the US.
The primary objectives of this investigational device exemption (IDE) clinical investigation are to assess the feasibility of using the Jarvik 2015 in pediatric patients with severe heart failure who require mechanical circulatory support. Feasibility will be assessed by evaluating the safety profile of the Jarvik 2015 device in eligible subjects.
- Conditions
- Pediatric Heart Failure
- Being tested
- Surgical placement of the Jarvik 2015 VAD, Surgical Placement of Jarvik 2015 VAD
- Keywords
- ventricular assist device, congenital heart disease, heart failure
- Medical subject headings
- Heart Defects, Congenital, Heart Failure
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Surgical placement of the Jarvik 2015 VADDevice
The Jarvik 2015 VAD is a miniaturized, fully implantable, continuous flow left ventricular assist device.
Surgical Placement of Jarvik 2015 VADProcedure or surgery
Surgical Implant of the Jarvik 2015 VAD is a miniaturized, fully implantable, continuous flow left ventricular assist device.
| Study group | Role | What they receive |
|---|---|---|
| Jarvik 2015 Device VAD | Experimental | New, experimental continuous flow VAD Receives: Device: Surgical placement of the Jarvik 2015 VAD; Procedure: Surgical Placement of Jarvik 2015 VAD |
What is being measured
The primary outcome is the main question the study is designed to answer.
Clinical Feasibility
To assess the clinical feasibility of the investigational Jarvik 2015 VAD by evaluating survival in the absence of severe neurological impairment or death, or device failure up to the clinical endpoint defined as transplant, recovery or 30 days of support
Measured: 30 days or transplant/recovery (whichever comes first)
Adverse Events
To evaluate the protocol defined (INTERMACS version 5.0) serious adverse events on Jarvik 2015 support up to transplant, recovery or 30 days of support
Measured: 30 days or transplant/recovery (whichever comes first)
Technical, surgical, and clinical milestones assessed by feasibility milestones
To describe the technical, surgical and clinical feasibility by achieving specific technical, surgical, and clinical milestones that typically accompany a successful VAD support run
Measured: up to 180 days or transplant/recovery
Pivotal Trial continuation assessed by exploratory primary and secondary endpoints
To evaluate patients with respect to exploratory primary and secondary endpoints to inform the choice of appropriate primary and secondary endpoints for the pivotal trial.
Measured: 12-months post-explant
Secondary outcomes (26)
Incidence of Adverse Events per patient days of VAD support
The incidence rate of protocol-defined AEs (INTERMACS, version 5) per patient-day of VAD support up to the first 180 days post-implant.
Measured: 180 days post-implant
Incidence of Adverse Events related to device
Incidence rate of protocol-defined AEs possibly, probably, or definitely related to the device per day of mechanical circulatory support, up to the first 180 days post-implant.
Measured: 180 days post-implant
Neurological dysfunction
The incidence of new neurological dysfunction up to 180 days post-implant.
Measured: 180 days post-implant
Pediatric Stroke Outcome Measure Neurological Exam (PSOM-NE) score (0 - 10 scale, higher = worse outcome)
Pediatric Stroke Outcome Measure-Neurological (PSOM-NE) score measured at 180 days post-implant or immediately prior to explant, and at 12 months post-explant.
Measured: 180 days and 12 months post-explant
King's Outcome Scale for Childhood Head Injury score (0 -5 scale, higher = worse outcome)
King's Outcome Scale for Childhood Head Injury (KOSCHI) score measured at 180 days post-implant or immediately prior to explant, and at 12 months post-explant.
Measured: 180 days and 12 months post-explant
Pediatric Stroke Recurrence and Recovery Questionnaire score (0 -10 scale, higher = worse outcome)
Pediatric Stroke Recurrence and Recovery Questionnaire (RRQ) measured at 180 days post-implant or immediately prior to explant, and at 12 months post-explant.
Measured: 180 days and 12 months post-explant
Vineland Adaptive Behavior Scales score (scoring and scale different by domain)
Vineland Adaptive Behavior Scales (VABS II) measured at 12 months post-explant.
Measured: 12 months post-explant
Pediatric Quality of Life score (0-4 scale per domain, higher = worse outcome)
PedsQL20 measured at 180 days post-implant or immediately prior to explant and 12 months post-explant.
Measured: 12 months post-explant
Ventricular Assist Device Quality of Life score (scoring and scale different per question)
VAD QL measured at 30 and 90 days post-implant, and every 90 days thereafter, while on Jarvik 2015 VAD support.
Measured: 30 days, 90 days, 12 months post-explant
Paralytics discontinuation
Time to discontinuation of paralytics
Measured: 12 months post-explant
TPN discontinuation
Time to discontinuation of total parenteral nutrition (TPN)
Measured: 12 months post-explant
Extubation
Time to extubation
Measured: 30 days post-implant
Inotropic agents
Time to discontinuation of inotropic agents
Measured: 12 months post-explant
Sedation
Time to discontinuation of sedation such that subject is alert and interactive (e.g., engaging in age-appropriate play).
Measured: 30 days post-implant
MRI
Brain Magnetic Resonance Imaging (MRI) performed 12 months post-explant to assess for clinically silent neurologic injuries.
Measured: 12 months post-explant
Survival in absence of severe neurological impairment
Overall survival in the absence of a severe neurologic impairment and in the absence of device failure at 180 days following VAD implant and meeting any of the following outcomes: Survival to induction of anesthesia for cardiac transplant surgery, Recovery (removal of VAD and alive at 30 days post-explant), Survival at 180 consecutive days of VAD support
Measured: 180 days or tranplant/recovery (whichever comes first)
Overall survival in the absence of device failure
Overall survival in the absence of device failure but without regard for neurologic status, meeting any of the following outcomes: Survival to induction of anesthesia for cardiac transplant surgery, Survival to recovery (removal of Jarvik 2015 VAD and alive at 30 days post-explant), Survival at 180 consecutive days of Jarvik 2015 VAD support
Measured: 180 days or tranplant/recovery (whichever comes first)
Survival at 30 days post-implant
Survival at 30 days post-implant
Measured: 30 days post-implant
Survival at 180 days post-implant
Survival at 180 days post-implant
Measured: 180 days post-implant
Survival at 12 months post-explant
Survival at 12 months post-explant
Measured: 12 months post-explant
Time to pump failure
Time to first pump failure
Measured: device explant
Incidence rate of pump failure
Incidence rate of pump failures
Measured: device explant
Time to first pump exchange
Time to first pump exchanges
Measured: device explant
Incidence rate of pump exchange
Incidence rate of pump exchanges
Measured: device explant
Creatinine level
Proportion of subjects with a creatinine level below the ULNULN
Measured: 180 days or immediately prior to explant
ALT level
Proportion of subjects with an alanine aminotransferase (ALT) level below the ULNULN
Measured: 180 days or immediately prior to explant
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Nov 2016 (estimated)
- Study start22 Oct 2018
- Primary completion9 Jun 2023
- Study completion15 Sep 2023 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Pediatric Heart FailureStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Early Phase 1
- Primary purpose
- Device feasibility
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- Jarvik 2015
- Masking
- None (open label)
- Enrolment
- 7 participants (actual)
Sponsor and investigators
- Lead sponsor
- Carelon Research
- Sponsor type
- University, hospital or other
- Collaborators
- National Heart, Lung, and Blood Institute (NHLBI), Jarvik Heart, Inc.
- Responsible party
- Sponsor
- Investigators
- William T Mahle, MD, Study chair, Children's Hospital of Atlanta, Emory University School of Medicine
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02954497
- Sponsor's protocol ID
- C01367
- Acronym
- PumpKIN
- Status last verified
- Nov 2022
- First submitted
- 31 Oct 2016
- Last updated
- 21 Sep 2023
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- Yes: Limited use data set will be made available through NHLBI after the conclusion of the trial.
Study at a glance
From the registry record, last updated by the sponsor on 21 Sep 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Pumps for Kids, Infants, and Neonates
- ClinicalTrials.gov ID
- NCT02954497
- Acronym / sponsor ID
- PumpKIN / C01367
- Conditions
- Pediatric Heart Failure
- Keywords
- ventricular assist device, congenital heart disease, heart failure
- Phase
- Early Phase 1
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 7 participants (actual)
- Lead sponsor
- Carelon ResearchUniversity, hospital or other
- Collaborators
- National Heart, Lung, and Blood Institute (NHLBI), Jarvik Heart, Inc.
- Study start
- 22 Oct 2018 (actual)
- Primary completion
- 9 Jun 2023 (actual)
- Study completion
- 15 Sep 2023 (estimated)
- First posted
- 3 Nov 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
PumpKIN is a multicenter, prospective, single-arm feasibility study; Evaluating the investigational Jarvik 2015 VAD in pediatric patients with heart failure. This feasibility trial will enroll 10 subjects at up to 7 sites in the US.
The primary objectives of this investigational device exemption (IDE) clinical investigation are to assess the feasibility of using the Jarvik 2015 in pediatric patients with severe heart failure who require mechanical circulatory support. Feasibility will be assessed by evaluating the safety profile of the Jarvik 2015 device in eligible subjects.
Study design
- Primary purpose
- Device feasibility
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- Jarvik 2015
| Arm | Type | Receives |
|---|---|---|
| Jarvik 2015 Device VAD | Experimental | Device: Surgical placement of the Jarvik 2015 VAD, Procedure: Surgical Placement of Jarvik 2015 VADNew, experimental continuous flow VAD |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Surgical placement of the Jarvik 2015 VADThe Jarvik 2015 VAD is a miniaturized, fully implantable, continuous flow left ventricular assist device. | Device | Jarvik 2015 Device VAD |
| Surgical Placement of Jarvik 2015 VADSurgical Implant of the Jarvik 2015 VAD is a miniaturized, fully implantable, continuous flow left ventricular assist device. | Procedure or surgery | Jarvik 2015 Device VAD |
Primary outcome
Clinical Feasibility
Time frame: 30 days or transplant/recovery (whichever comes first)
To assess the clinical feasibility of the investigational Jarvik 2015 VAD by evaluating survival in the absence of severe neurological impairment or death, or device failure up to the clinical endpoint defined as transplant, recovery or 30 days of support
Adverse Events
Time frame: 30 days or transplant/recovery (whichever comes first)
To evaluate the protocol defined (INTERMACS version 5.0) serious adverse events on Jarvik 2015 support up to transplant, recovery or 30 days of support
Technical, surgical, and clinical milestones assessed by feasibility milestones
Time frame: up to 180 days or transplant/recovery
To describe the technical, surgical and clinical feasibility by achieving specific technical, surgical, and clinical milestones that typically accompany a successful VAD support run
Pivotal Trial continuation assessed by exploratory primary and secondary endpoints
Time frame: 12-months post-explant
To evaluate patients with respect to exploratory primary and secondary endpoints to inform the choice of appropriate primary and secondary endpoints for the pivotal trial.
26 secondary outcomes
Incidence of Adverse Events per patient days of VAD support
Time frame: 180 days post-implant
Incidence of Adverse Events related to device
Time frame: 180 days post-implant
Neurological dysfunction
Time frame: 180 days post-implant
Pediatric Stroke Outcome Measure Neurological Exam (PSOM-NE) score (0 - 10 scale, higher = worse outcome)
Time frame: 180 days and 12 months post-explant
King's Outcome Scale for Childhood Head Injury score (0 -5 scale, higher = worse outcome)
Time frame: 180 days and 12 months post-explant
Pediatric Stroke Recurrence and Recovery Questionnaire score (0 -10 scale, higher = worse outcome)
Time frame: 180 days and 12 months post-explant
Vineland Adaptive Behavior Scales score (scoring and scale different by domain)
Time frame: 12 months post-explant
Pediatric Quality of Life score (0-4 scale per domain, higher = worse outcome)
Time frame: 12 months post-explant
Ventricular Assist Device Quality of Life score (scoring and scale different per question)
Time frame: 30 days, 90 days, 12 months post-explant
Paralytics discontinuation
Time frame: 12 months post-explant
TPN discontinuation
Time frame: 12 months post-explant
Extubation
Time frame: 30 days post-implant
Inotropic agents
Time frame: 12 months post-explant
Sedation
Time frame: 30 days post-implant
MRI
Time frame: 12 months post-explant
Survival in absence of severe neurological impairment
Time frame: 180 days or tranplant/recovery (whichever comes first)
Overall survival in the absence of device failure
Time frame: 180 days or tranplant/recovery (whichever comes first)
Survival at 30 days post-implant
Time frame: 30 days post-implant
Survival at 180 days post-implant
Time frame: 180 days post-implant
Survival at 12 months post-explant
Time frame: 12 months post-explant
Time to pump failure
Time frame: device explant
Incidence rate of pump failure
Time frame: device explant
Time to first pump exchange
Time frame: device explant
Incidence rate of pump exchange
Time frame: device explant
Creatinine level
Time frame: 180 days or immediately prior to explant
ALT level
Time frame: 180 days or immediately prior to explant
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Sep 2023.
- Individual participant dataSharing planned: Yes. Limited use data set will be made available through NHLBI after the conclusion of the trial.
Related trials for Pediatric Heart Failure
RecruitingPhase 2/3
Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)
Heart Failure, Left Ventricular Systolic Dysfunction
Enrolling by invitation
EXCOR Active Driving System for the EXCOR Pediatric VAD IDE Study
Heart Failure, Transplant; Failure, Heart
RecruitingPhase 3
A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction
Left Ventricular Systolic Dysfunction, Heart Failure (Pediatric)
Not yet recruitingPhase 4
A Phase IV, Two-part, Open-label Study Assessing the Pharmacokinetics, Safety and Pharmacodynamics of Spironolactone Oral Suspension in Pediatric Patients
Edema Due to Heart Failure or Cirrhosis
RecruitingObservational study
Exploratory Study on Bio-signal Telemonitoring Using Electronic Textiles in a Pediatric Acute and Critical Care Setting
Heart Failure
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
William T Mahle, MD study chair
Children's Hospital of Atlanta, Emory University School of Medicine
7 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Early Phase 1 study testing Surgical placement of the Jarvik 2015 VAD and Surgical Placement of Jarvik 2015 VAD in people with Pediatric Heart Failure, run by Carelon Research at 7 sites in United States.
The full registered description is in the About this study section and the official record.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 21 Sep 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 7 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Early Phase 1 (sometimes called Phase 0) studies give a very small amount of a treatment to a few people, mainly to see how the body handles it.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Clinical Feasibility (time frame: 30 days or transplant/recovery (whichever comes first)). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Sep 2023.